Lib Dems in Essex suggest leadership change

The leader of Colchester City Council says "time's up" for Sir Ed Davey.
Business Wire

LIB Therapeutics Appoints David Cory as Chief Executive Officer as Lead Clinical Programs Achieve Phase 3 Completion

CINCINNATI--(BUSINESS WIRE)--LIB Therapeutics Inc. (LIB), a late-stage biopharmaceutical company developing subcutaneous and oral PCSK9 inhibitor therapies for patients at very high and high-risk of ...
pharmaphorum

LIB takes aim at cholesterol market with new PCSK9 option

Privately-held drug developer LIB Therapeutics has claimed FDA approval for a new once-monthly PCSK9 inhibitor – Lerochol – that can be used to reduce cholesterol levels. The injectable product has ...
Business Wire

LIB Therapeutics Announces Publication of Phase 3 Study of Lerodalcibep in Homozygous Familial Hypercholesterolemia (HoFH) in Lancet Diabetes & Endocrinology

LIBerate-HoFH study was part of a global registration-enabling Phase 3 program of > 2,900 patients Biologics license application for lerodalcibep submitted to FDA in December 2024 ...
Yahoo Finance

LIB Therapeutics Launches LEROCHOL® (lerodalcibep-liga) in the United States with a Patient-First Approach to Access and Affordability

Once-monthly, third-generation PCSK9 inhibitor now available with direct-to-patient cash-pay option at $199 per month, a substantial discount to other PCSK9 inhibitors direct-to-patient cash prices ...
The Caledonian-Record

LIB Therapeutics Announces Results from Presentations on LEROCHOL® (lerodalcibep-liga) at the 2026 European Atherosclerosis Society Meeting in Athens, …

LIB Therapeutics Inc. (LIB), a privately-held, biopharmaceutical company with a recently approved novel, monthly, small-dose, ...